Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

The managed care environment faces new pharmacoeconomic barriers with the increasing complexity of targeted therapies and introduction of novel agents in the treatment of HR+/HER2– metastatic breast cancer. Mutational testing is paramount to guide the appropriate selection of therapies in both the frontline setting and for disease progression. From a managed care perspective, the rising cost of managing metastatic breast cancer requires careful consideration of resource utilization. Experts will lead a discussion on strategies for managed care professionals to improve access to oral treatments for HR+/HER2– metastatic breast cancer, appropriately apply genomic testing to ensure biomarker-directed therapy, and facilitate coverage policies that support patient access to care.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply the guideline recommendations for mutational testing and associated treatment selection in HR+ metastatic breast cancer.
• Compare recent clinical trial data for triplet regimen with the historic standard of care in frontline treatment algorithms for HR+/HER2– metastatic breast cancer.
• Analyze the evolving role of oral targeted agents and selective estrogen receptor degraders in the management of HR+/HER2– metastatic breast cancer.
• Investigate the impact of recent clinical updates on formulary decisions, treatment pathways, and resource allocation for patients with HR+/HER2– metastatic breast cancer within operational and managed care frameworks.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-086-H01-P. The activity is available for CE credit through April 10, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Simone Ndujiuba, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose: Employee of PBM: Prime Therapeutics.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Abigail Shockley, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

 
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms